TheraRadar
← Back
Data updated: Jun 28, 2026

EZRA VENTURES

Generics

EZRA VENTURES is a generic drug manufacturer focused on Neurology.

2023
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

EZRA VENTURES's Key Drugs

EZRA VENTURES's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

EZRA VENTURES's Recent FDA Approvals

New NDA/BLA approvals for EZRA VENTURES over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

EZRA VENTURES's Therapeutic Areas

EZRA VENTURES's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
1 drugs

EZRA VENTURES's Top Competitors

EZRA VENTURES's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

EZRA VENTURES Pipeline Snapshot

Active clinical trials for EZRA VENTURES across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling